Lates News

Every AI Flash News, Huaxin Securities issued a research report on April 15th, giving Kangtuo Medical (688314.SH) a "buy" rating. The rating reasons mainly include: 1) PEEK material continues to replace, product upgrades maintain stable gross profit margin; 2) M&A enters the oral medical track, self-research continuously enriches the pipeline and M&A; 3) The industrialization trend of brain-machine interface drives the growth of demand for neurosurgery. (Daily Economic News)